The combined treatment induces G2/M cell cycle arrest and disrupts the physical association of CD44 with NANOG and MDR1 in MDA-MB-231 cells, thus overcoming breast cancer resistance and promoting cancer cell death [123,124]. The gene discussed is NANOG; the disease is breast carcinoma.